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A B S T R A C T
Background: In the United States endometrial carcinoma is the most common female gynecologic malignancy.
An average of more than 60,000 new cases of endometrial carcinomas have been diagnosed yearly over the past
5 years, with a higher incidence occurring in the central Appalachian states of Ohio and West Virginia. In the
U.S., the national average of newly diagnosed endometrial carcinomas is 26.8 in every 100,000 women, while in
the states of Ohio and West Virginia the average is 30.5 and 31.1 in every 100,000 women, respectively. This
notable increase in the incidence of endometrial carcinomas may be due a variety of elevated risk factors in-
cluding but not limited to: tobacco use, obesity, and genetic predisposition of the predominant demographic. The
American Cancer Society estimates that approximately 55,000 new cases of endometrial carcinoma will be
diagnosed in 2020 yet, this disease is widely considered understudied and under-represented in mainstream
cancer research circles.
Methods: The aim of this study was to quantitate the co-expression of two DNA repair proteins poly-ADP-ribose
polymerase 1 and 2 (Parp-1 and Parp-2) by enzyme- linked immuno-sorbent assay (ELISA) in 60 endometrioid
endometrial tumor samples and compare their expression to matched non-malignant endometrial tissue from the
same corresponding donors from central Appalachia.
Results: We found that Parp-1 was significantly overexpressed in endometrial carcinoma relative to corre-
sponding normal tissue. This overexpression implicates Parp inhibition therapy as a possible treatment for the
disease. Our results also found a protective effect of native Parp-2 expression in non-malignant endometrial
tissue with each 1 ng/mL increase in PARP-2 concentration in normal tissue was associated with a 10 % re-
duction in the hazard of tumor progression (HR = 0.90; p = 0.039) and a 21 % reduction in the hazard of death
(HR = 0.79; p = 0.044).
Conclusions: This study demonstrated the over-expression of the druggable target Parp-1 in endometrial ade-
nocarcinoma and observed a strong negative correlation of native Parp-2 expression and disease progression via
the quantification of the Parp proteins using enzyme- linked immuno-sorbent assay (ELISA) assays.
1. Background
Parp-1 and Parp-2 enzymes are DNA repair proteins in the PARP
family of nuclear enzymes involved in a number of cellular processes
including DNA-repair, genetic stability, and programmed cell-death
[1,2]. The primary role of Parp-1 and Parp-2 within the cell is to
https://doi.org/10.1016/j.prp.2020.152965
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identify and initiate a repair response to single-strand (SSB) and double-
strand (DSB) DNA breaks during homologous recombination [1–8].
There is, however, a growing body of evidence to suggest that the Parp
family of proteins, specifically Parp-2 may play a more diverse role
within the cell and could possibly serve as prognostic markers in the
cancer setting [9–11].
The roles of the Parp-1 and Parp-2 proteins in the repair process of
damaged DNA are by far the most characterized functions of the family
of Parp proteins and have been targets of recently developed anticancer
therapies for the treatment of ovarian cancer [7,12,13]. These therapies
are now being examined for their utility in a variety of other malig-
nancies with and without radiation or other chemotherapeutic agents in
ovarian, breast, prostate, rectal, lung, pancreatic, peritoneal, head and
neck, brain, squamous cell carcinomas and sarcomas, to list a few
[14–16]. Clinical trials investigating Parp inhibitors for the treatment of
endometrial cancer are also underway (NCT03586661, NCT01237067,
NCT03572478, and NCT03951415).
Both Parp-1 and Parp-2 recognize SSB and DSB DNA breaks via their
Fig. 1. Hematoxylin & eosin staining of a grade -2 and -3 endometrial carcinoma.
A) 100 X magnification of a grade-2 endometrial carcinoma showing a 6 %–50 % non-squamous solid growth pattern. Insert shows a 200 X magnification.
B) 100 X magnification of a grade-3 endometrial carcinoma showing a>50 % non-squamous solid growth pattern. Insert shows a 200 X magnification.
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zinc-finger DNA binding domains [8,17,18]. After Parp-1 directly binds
to the altered DNA, Parp-1 increases its catalytic activity and uses NAD
+ to create polymers of poly(ADP-ribose) (PAR) and transfers them to
acceptor proteins, including additional Parp. The accumulation of the
resulting (PAR) polymers recruits various DNA repair proteins to the
site of damage. Subsequent to the PAR accumulation DNA polymerases
alpha and beta are recruited to the damaged DNA and facilitate DNA
repair. In somatic tissues, this function of Parp-mediated DNA repair
serves to limit the accumulation of genetic alterations resulting from
replication and oxidative damage [19]. In the cancer setting however,
malignant cells have been shown to utilize the Parp family of proteins
to promote chemotherapy and radiotherapy resistance. To defeat this
Parp-mediated therapy resistance, Parp inhibitors have been developed.
In conjunction with radiation therapy and the classic platinum based
chemotherapeutic agents Cisplatin, Oxaliplatin, and Carboplatin, Parp
inhibitors are used to sensitize malignant cells to DNA damage induced
by chemotherapy [6,7].
When PARP inhibitors are present, PARP-dependent repair systems
are not activated due to catalytic inhibition and/or direct trapping. This
results in replication fork stalling during DNA replication, and creation
of DSBs. In cells where homologous recombination (HR) is not impaired
(such as in the case of wild-type BRCA), DSBs are repaired and re-
plication may restart, resulting in cell survival. However, in BRCA-de-
ficient cells where homologous recombination is impaired, DSB cannot
be efficiently repaired and DSB accumulates, resulting in cell death
[20].
Parp inhibitors Olaparib, Niraparib, Rucaparib, and Talazoparib
have been developed and approved for the treatment of a variety of
malignancies [21–28]. These inhibitors directly bind to the Parp mo-
lecules and prevent their interaction with damaged DNA. Although
Parp inhibition therapies have been approved for the treatment of
ovarian cancer, fallopian tube cancer, and primary peritoneal cancer; to
date their utility has not been widely investigated for endometrial
cancer.
In addition to their DNA repair function, Parp proteins have been
shown to regulate a number of essential processes that directly influ-
ence the growth and maintenance of tumors such as metabolic, angio-
genetic, and proliferation pathways [18,29–31]. All this emerging lit-
erature on the multifaceted nature and function of Parp proteins within
cancer opens the opportunity to use Parp immunostaining expression as
a potential prognostic assay in the clinical setting. Parp-2 over-ex-
pression in particular may demonstrate clinical significance in pre-
dicting the virulence of a malignancy.
Parp-2 has been shown to be involved in dysregulated malignant
processes including, but not limited to, proliferative signaling, angio-
genesis, and metabolic shift. All of these cellular processes are posi-
tively correlated to higher-grade of solid malignant tumors, including
high-grade endometrial cancer. In the light of all this, the intent of our
study was to help filling the knowledge gap on the expression of Parp-1
and Parp-2, for their potential use as druggable targets in the treatment
of endometrioid endometrial cancer. We examined 60 patients from
southern Ohio and southwestern West Virginia diagnosed with
Endometrioid Endometrial Adenocarcinoma with an International
Federation of Gynecology and Obstetrics (FIGO) score grade-2 or above
over the course of 3 years. The FIGO grading system is based on the
architectural features of the endometroid endometrial carcinoma [32].
Grade-2 endometrioid endometrial carcinomas show a 6 %–50 % non-
squamous solid growth pattern, while grade-3 endometrioid en-
dometrial carcinomas show greater than 50 % non-squamous solid
growth pattern. Nuclear atypia, which is more that what would be
expected for architectural grade, increases the FIGO grade by one [32]
(Fig. 1). The aims of this investigation were to establish the protein
expression profiles of Parp-1 (Poly-ADP-ribose polymerase-1) and Parp-
2 (Poly-ADP-ribose polymerase-2), two cancer-associated DNA repair
proteins, in tumor tissue compared with matched non-malignant en-




De-identified research samples were obtained from the non-profit,
open access biorepository bank at the Edwards Comprehensive Cancer
Center at Cabell Huntington Hospital, Huntington, WV. Endometrioid
Endometrial Cancers with a FIGO score of equal or greater than 2 were
obtained from the tumor bank along with their corresponding normal
tissue samples. A sample cohort of 40 grade-2 endometrioid en-
dometrial adenocarcinomas and 20 grade-3 endometrioid endometrial
carcinomas were collected (Table 1). Each of the patient samples were
from total hysterectomy specimens. The tumor samples and their mat-
ched normal tissue counterparts were collected on ice in the surgical
pathology department with no more than 15 min of time elapsed from
surgery. Tumor tissue and corresponding normal tissue were identified
based upon gross examination by either the pathologist on call or by the
attending pathology assistant. Once the tissue identifications were es-
tablished, representative sections were cut using aseptic technique from
both the malignant tissue and the grossly normal tissue. Blade changes
were made between cutting of the tumor tissue and the non-tumor
tissue. After collection, the samples were immediately flash frozen in
liquid nitrogen and transferred to liquid nitrogen vapor phase storage
for not more than 3 years.
2.2. ELISA assay
Our study utilized Parp-1 and Parp-2 enzyme- linked immuno-sor-
bent assay (ELISA) kits purchased from Aviva Systems Biology®. After
screening and sample selection was complete, the samples were thawed
at room temperature. After this initial thaw, the samples were rinsed
with sterile 1X PBS (Phosphate Buffered Saline, Thermo Fisher). The
samples were mechanically homogenized with a sterile glass rod in
sterile 15 mL centrifuge tubes in 5 mL of 1X PBS without added pro-
tease inhibitors. Additional 1X PBS was then added to the tissue
homogenates to achieve a volume of 10 mL. These homogenates were
then subjected to an additional freeze/thaw cycle at −20 °C for 24 h
followed by thawing at room temperature to further lyse the cell
membranes. After the final thaw at room temperature, the samples were
vortexed and subsequently centrifuged for 5 min at 5000×g at 4 °C as
per assay specifications. The supernatant was removed and protein




PT1A stage 32 (53 %)
PT1B stage 17 (28 %)
PT2 stage 6 (10 %)
PT3A stage 2 (3 %)
PT3B stage 2 (3 %)
PT4 stage 1 (2%)
Grade 2 40 (67 %)
Grade 3 20 (33 %)
Reg. Lymph Node 3 (5 %)
Cerv. Stroma Invasion 9 (15 %)
Myometrial Invasion % 40.54± 33.49
PARP-1 Tumor 19.96± 8.5
PARP-1 Normal 9.64± 6.14
PARP-2 Tumor 7.63± 5.23
PARP-2 Normal 8.93± 6.24
Death 6 (11 %)
Progression 13 (22 %)
Shown are the mean for continuous variables and count (per-
centage) for categorical variables.
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supernatant were then plated on the ELISA plates supplied with the
purchased kits and the assay protocol was followed. The ELISA assay
resulted in various absorbance values corresponding to levels of target
protein in each sample. The absorbance values that were obtained were
then transferred to an in-house data analysis software developed using
the Windows Microsoft Excel platform to calculate the standard de-
viations for each group and compared the average absorbance for each
group to the standardized controls. Each test group for each of the
proteins of interest consisted of four replicates. The assay specific
controls were run with each plate to ensure optimal accuracy of the
results.
2.3. Statistical analyses
Descriptive statistics were compiled where appropriate and uni-
variate comparisons of PARP concentrations between tissue types were
made with Mann-Whitney U tests and stratified by grade. To visually
depict these results, plots were constructed to display underlying data
and mean PARP concentrations along with 95 % confidence intervals.
Hazard ratios for death and progression were calculated via Cox pro-
portional hazard models. Ordinary least squares regression was used to
assess the relationship between myometrial invasion percentage and
PARP, while logistic models were used for PARP and the regional lymph
node involvement or cervical stroma invasion, the latter two being
combined into one group due to small percentages. All models were age
adjusted, and all analyses were performed with Stata v15.1 (StataCorp,
College Station, TX).
3. Results
The success of PARP inhibitors in the treatment of ovarian cancer
serves as a model for the appropriate use of these targeted therapies in a
variety of malignancies. We have studied the expression of Parp-1
(Poly-ADP-ribose polymerase-1) and Parp-2 (Poly-ADP-ribose poly-
merase-2) on 60 patients from southern Ohio and southwestern West
Virginia diagnosed with Endometrioid Endometrial Adenocarcinoma
with an International Federation of Gynecology and Obstetrics (FIGO)
score grade-2 or above over the course of 3 years. Fig. 1 shows a he-
matoxylin and eosin staining of a grade-2 endometrioid endometrial
carcinomas showing 6–50 % non-squamous solid growth pattern, while
grade-3 endometrioid endometrial carcinomas show greater than 50 %
non-squamous solid growth pattern.
The mean participant age was 64 years. Most patients presented
with stage 1 primary tumors (PT1A plus PT1B = 49/60 cases; 81 %).
Two thirds (40/60 cases; 67 %) of the tumors were grade 2. Three
participants (5 %) had regional lymph node involvement, while 9 (15
%) had cervical stroma invasion and the mean myometrial invasion
percentage was 40.5. Thirteen (22 %) participants had documented
disease progression, while 6 (11 %) died during the course of the study
(Table 1).
In this investigation, we aimed at establishing the protein expres-
sion profiles of PARP-1 and -2 cancer associated DNA repair proteins in
tumor tissue compared with matched non-malignant endometrial tissue
and to stratify this data based on the grade of the malignancy. Figs. 2
and 3 combined with Table 2 display the results of this aim. PARP-1
concentration was significantly higher in tumor tissue compared to
normal for both grades 2 and 3 (both p<0.001). Interestingly, PARP-2
concentration was significantly higher for tumor tissue in grade 3
(p<0.001), but was significantly higher for normal tissue in grade 2 (p
= 0.001).
Further, age-adjusted survival analysis results demonstrated that
PARP-1 concentration was not associated with neither death nor pro-
gression (death PARP-1 tumor p = 0.632; progression PARP-1 tumor p
= 0.332; death PARP-1 normal p = 0.552; progression PARP-1 normal
p = 0.652). PARP-2 tumor concentration trended in a hazardous di-
rection for both death and progression (death HR = 1.09; progression
HR = 1.10, per 1 ng/mL increase), although the study was under-
powered to garner statistical support (death p = 0.267, progression p
= 0.067). PARP-2 concentration in normal tissue, however, did have
statistical support for a protective effect. Each 1 ng/mL increase in
PARP-2 concentration in normal tissue was associated with a 10 %
reduction in the hazard of progression (HR = 0.90; p = 0.039) and a
21 % reduction in the hazard of death (HR = 0.79; p = 0.044). See
Table 3.
As an exploratory aim, we were interested in investigating if a re-
lationship exists between PARP concentration and myometrial invasion
percentage. We did not find any associations supporting this (PARP-1
tumor p = 0.481; PARP-1 normal p = 0.995; PARP-2 tumor p = 0.592;
PARP-2 normal p = 0.939). Also, no associations were found between
PARP and probability of regional lymph node involvement or cervical
stroma invasion (PARP-1 tumor p = 0.472; PARP-1 normal p = 0.627;
PARP-2 tumor p = 0.858; PARP-2 normal p = 0.343).
These results strongly suggest that more studies should be con-
ducted toward understanding the clinical utility of Parp-1 and -2 in-
hibition therapy for the treatment and care management of endometrial
cancer.
4. Discussion
We report here an evaluation of PARP-1 and -2 concentrations
Fig. 2. PARP-1 expression (ng/mL) in extracts from matched normal en-
dometrial tissue compared to grade-2 and grade-3 endometrial tumors mea-
sured by ELISA assay.
Fig. 3. PARP-2 expression (ng/mL) in extracts from matched normal en-
dometrial tissue compared to grade-2 and grade-3 endometrial tumors mea-
sured by ELISA assay.
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relative to grade of the disease and to clinical progression and survival
in an endometrioid endometrial adenocarcinoma patient cohort. Our
study examined 60 patients from southern Ohio and southwestern West
Virginia diagnosed with Endometrioid Endometrial Adenocarcinoma
with a FIGO score grade-2 or above over the course of 3 years (Table 1).
We studied the expression profiles of Parp-1 and -2 in tumor tissue
compared with matched non-malignant endometrial tissue and strati-
fied this data based on the grade of the malignancy.
The Parp-1 and Parp-2 enzymes are DNA repair proteins in the
PARP family of nuclear enzymes involved in a number of cellular
processes including DNA-repair, genetic stability, and programmed cell-
death [1,2].
In addition to their DNA repair function, Parp proteins have been
shown to regulate a number of essential processes that directly influ-
ence the growth and maintenance of tumors such as metabolic, angio-
genetic, and proliferation pathways [18,29–31]. In fact, both Parp-1
and Parp-2 have upstream regulatory effects on cellular oxidative me-
tabolic processes via the Parp/SIRT1 protein interaction [3,33,34].
Parp-2 has been shown to directly bind to the SIRT1 gene promoter
where it blocks SIRT1 transcription. This results in significant impedi-
ments to mitochondrial biogenesis with a shift of cellular processes
towards glycolytic metabolism, which is one of well-known hallmarks
of the carcinogenic process (shift from traditional oxidative respiration
to aerobic glycolysis) [4,35]. This is known as the “Warburg effect” and
this effect is seen in high-grade neoplasms including grade-3 en-
dometrial carcinomas. Our data showed that there is a statistically
significant increased expression in grade-2 and -3 tumors compared to
their normal matched tissues (Table 2 and Figs. 2 and 3). Interestingly,
PARP-2 concentration was significantly higher for tumor tissue in grade
3 (p<0.001), but was significantly higher for normal tissue in grade 2
(p = 0.001).
Parp proteins have been found to promote tumor angiogenesis by
SIRT1 inhibition. Angiogenesis is a crucial function in the development,
growth, and maintenance of healthy tissues [36–39]. New blood vessel
formation serves to oxygenate and nourish healthy and growing tissues,
however this process is also utilized by tumors. Just as in healthy tis-
sues, malignant tumors rely on angiogenesis to nourish the rapidly
growing neoplastic mass of cells [40]. In addition to allowing a tumor
to rapidly increase in size, the new blood vessels formed by tumor
angiogenesis provide a route for tumor metastasis and migration to
other locations within the body [36,41]. The Parp-1 protein has a well-
documented angiogenic effect; however, the specific molecular
pathways involved have yet to be determined. Our data on the ex-
pression levels of Parp-1 and -2 in grade-2 and -3 endometrioid en-
dometrial adenocarcinoma is in agreement with the idea that tumors
need increased angiogenesis for their growth and homeostasis in com-
parison to normal tissues.
Recently, Parp-2 has also been found to promote proliferative sig-
naling via the suppression of Transforming Growth Factor Beta-1
Pathway Regulation [37]. TGF-β is a polypeptide protein involved in a
variety of cellular functions including cell cycle regulation, cell growth,
cell proliferation, cell differentiation and apoptosis [42]. The TGF-β
pathway is an important tumor suppressor pathway that promotes
tissue homeostasis and cell differentiation particularly of endothelial
cells. TGF-β is suppressed in the carcinogenesis of a variety of cancers
including endometrial cancer [42]. Our data that PARP-2 is more ex-
pressed in higher-grade endometrioid endometrial cancer is also in
agreement with the fact that more aggressive tumors may proliferate
more abundantly, and could display a suppressed TGF-β pathway.
From a therapy point of view, it has been widely shown that ma-
lignant cells utilize the Parp family of proteins to promote che-
motherapy and radiotherapy resistance. To defeat this Parp-mediated
therapy resistance, Parp inhibitors have been developed. Parp inhibi-
tion therapies have been developed and approved for the treatment of a
variety of malignancies [21–28]. These inhibitors directly bind to the
Parp molecules and prevent their interaction with damaged DNA. This
effectively silences the Parp DNA repair activities, which promote
apoptosis of cells in which chemo-radiation therapies determined DNA
damage that cannot be repaired. In fact, in conjunction with radiation
therapy and the classic platinum based chemotherapeutic agents Cis-
platin, Oxaliplatin, and Carboplatin, Parp inhibitors have been used in
the clinics to sensitize malignant cells to DNA damage induced by
chemotherapy [6,7]. Platinum based chemotherapeutic drugs affect
rapidly dividing cancer cells by cross-linking DNA at adjacent N-7 po-
sitions on guanine bases. The crosslinks result in inhibited DNA repair
leading to DNA single-strand (SSB) and double-strand breaks (DSB). On
detection of a SSB or DSB, the recruitment and activation of PARP leads
to SSB and DSB repair via polymers of ADP-ribosylation of histones and
chromatin-remodeling enzymes, autoPARylation of PARP and recruit-
ment of PARP-dependent DNA repair proteins. Repaired DNA can
subsequently undergo replication, resulting in the survival of the cell
[43]. Radiation therapy also targets the DNA of rapidly dividing neo-
plastic cells and induces similar SSBs and DSBs which are repaired by
the Parp proteins [44]. From this knowledge, Parp inhibitors have been
developed to decrease the ability of cancer cells to repair DNA damage
induced by chemoradiation therapy.
Although Parp inhibition therapies have been studied and approved
for the treatment of ovarian cancer, fallopian tube cancer, and primary
peritoneal cancer; to date their utility has not been widely investigated
for endometrial cancer. To our knowledge, this is the first time that
PARP-1 and -2 expression have been measured in endometrial adeno-
carcinoma samples. Our findings that PARP-1 and -2 are expressed at
higher levels than matched normal tissue in patients affected by en-
dometroid endometrial carcinomas paves the way to further in-
vestigating the potential use of PARP-inhibitors in the treatment of
endometrial cancer. More studies are needed to determine if PARP-1
and -2 expression could be considered in the future as biomarkers to
Table 2
Comparisons of PARP proteins expression between tissue samples.
Normal Tumor p-value
Grade 2 PARP-1 9.78 (6.95) ; 8.42 [5.28–11.5] 19.1 (8.19) ; 19.3 [11.7–24.3] <0.001
PARP-2 11.1 (5.85) ; 10.7 [7.39–15.4] 6.73 (5.28) ; 6.39 [2.45–9.62] 0.001
Grade 3 PARP-1 9.37 (4.25) ; 9.62 [6.00–11.9] 21.7 (9.07) ; 21.9 [14.6–27.6] <0.001
PARP-2 4.50 (4.43) ; 3.04 [2.27–4.56] 9.44 (4.75) ; 8.88 [5.45–13.6] <0.001
Statistics within each cell are mean (standard deviation); median [1st quartile – 3rd quartile]. p-value derived from Mann-Whitney U test.
Table 3
Age-adjusted hazard of progression or death per one unit increase in PARP
expression.
Progression Death
PARP-1 Tumor HR = 0.97; p = 0.332 HR = 1.02; p = 0.632
(0.90–1.04) (0.93–1.12)
PARP-1 Normal HR = 0.97; p = 0.652 HR = 0.94; p = 0.552
(0.86–1.10) (0.80–1.13)
PARP-2 Tumor HR = 1.10; p = 0.067 HR = 1.09; p = 0.267
(0.99–1.23) (0.94–1.27)
PARP-2 Normal HR = 0.90; p = 0.039 HR = 0.79; p = 0.044
(0.81 – 0.99) (0.62 – 0.99)
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stratify the response of endometrial carcinoma patients to therapy with
Parp inhibitors.
5. Conclusions
This study to our knowledge demonstrated for the first time in en-
dometrial adenocarcinoma the over-expression of druggable targets via
the quantification of the Parp proteins that paves the way to the idea
that PARP inhibitors could be useful for the treatment of this en-
dometrial disease.
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